Malathion gel - Taro Pharmaceuticals

Drug Profile

Malathion gel - Taro Pharmaceuticals

Alternative Names: MALG

Latest Information Update: 21 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taro Pharmaceuticals USA
  • Class Antiparasitics; Organothiophosphorus compounds; Small molecules
  • Mechanism of Action Cholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pediculosis

Most Recent Events

  • 06 Aug 2012 Phase-III development is ongoing in USA
  • 22 Sep 2011 Taro Pharmaceuticals completes a phase III trial in Pediculosis in the US (NCT00927472)
  • 06 Jun 2011 Taro Pharmaceuticals completes enrolment in its phase II/III trial in Pediculosis (in children 6-24 months) in the US (NCT00752973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top